Fri, September 18, 2009
Thu, September 17, 2009
Wed, September 16, 2009
Tue, September 15, 2009
Mon, September 14, 2009
Fri, September 11, 2009
Thu, September 10, 2009
Wed, September 9, 2009
Tue, September 8, 2009
Mon, September 7, 2009
Fri, September 4, 2009
Thu, September 3, 2009
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009
Sun, August 30, 2009
Fri, August 28, 2009
Thu, August 27, 2009
Wed, August 26, 2009
Tue, August 25, 2009
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009
Thu, August 20, 2009
Wed, August 19, 2009
Tue, August 18, 2009
Mon, August 17, 2009
Sun, August 16, 2009
Fri, August 14, 2009
Thu, August 13, 2009
Wed, August 12, 2009
Tue, August 11, 2009
Mon, August 10, 2009
Sun, August 9, 2009
Fri, August 7, 2009
Thu, August 6, 2009
Wed, August 5, 2009
Tue, August 4, 2009
Mon, August 3, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009
Tue, July 28, 2009
Mon, July 27, 2009

Critical Outcome Technologies Inc. (COTI): Critical Outcome Technologies Inc. Withdraws Its Private Placement Offering


  Copy link into your clipboard //house-home.news-articles.net/content/2009/08/2 .. nc-withdraws-its-private-placement-offering.html
  Print publication without navigation Published in House and Home on , Last Modified on 2009-08-24 13:32:49 by Market Wire
          🞛 This publication is a summary or evaluation of another publication

LONDON, ONTARIO--(Marketwire - Aug. 24, 2009) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that it has withdrawn its non-brokered private placement offering due to market conditions. The offering was announced on June 10, 2009 and subsequently extended on July 23, 2009. The offering received strong interest from investors; however, market conditions and investor circumstances prevented a conclusion that met the needs of the Company within placement timeframes.

"We remain focused on advancing COTI-2, our lead oncology compound, towards a Phase 1 filing", said Michael Cloutier, Chief Executive Officer of COTI. "We will continue to monitor the capital markets and investor interest in the coming months and are confident that we will obtain the financing necessary to ensure the success of the Company".

About Critical Outcome Technologies Inc.

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development: small cell lung cancer, HIV integrase inhibitors, acute adult leukemia, multiple sclerosis, colorectal cancer and Alzheimer's disease.

For further information, visit the website at [ www.criticaloutcome.com ].


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Publication Contributing Sources

Similar House and Home Publications